What causes endometrial cancer

Overview

Endometrial cancer is a type of cancer that begins in the endometrium, which is the inner lining of the uterus. It is the most common gynecologic cancer in the United States. While the exact cause is complex and multifactorial, the fundamental process involves genetic mutations within endometrial cells that disrupt normal cell growth and division. These mutations lead to the formation of a malignant tumor.

What is the Endometrium?

The endometrium is a specialized mucous membrane lining the interior of the uterus. Its primary function is to prepare for pregnancy each month by thickening and becoming rich in blood vessels. If pregnancy does not occur, this lining is shed during menstruation. Hormones, particularly estrogen and progesterone, play a crucial role in regulating the growth and shedding of the endometrium.

The Role of Genetic Mutations

Like all cancers, endometrial cancer begins when cells in the endometrium acquire specific genetic mutations. These mutations alter the cell's DNA, which is the blueprint for cell function. These changes can lead to:

• Uncontrolled Cell Growth: Mutated cells divide and multiply far more rapidly than healthy cells.
• Failure to Die: Normal cells have a programmed lifespan and die off. Cancer cells often evade this process.
• Invasion: Cancer cells can invade surrounding tissues and, eventually, spread to distant parts of the body (metastasize).

These mutations can be inherited or acquired during a person's lifetime due to various factors.

Key Factors Contributing to Endometrial Cancer Development

While genetic mutations are the underlying cause, several factors can increase a person's risk of developing these mutations and subsequently endometrial cancer. These are often related to hormonal influences, particularly estrogen:

Hormonal Imbalances and Estrogen Exposure

Estrogen is a primary hormone that stimulates the growth of the endometrium. When the endometrium is exposed to estrogen for prolonged periods without the balancing effect of progesterone, it can lead to abnormal cell growth (hyperplasia), which can sometimes progress to cancer. Factors that increase unopposed estrogen exposure include:

• Early Menarche (first period) and Late Menopause: This results in a longer reproductive lifespan with more cycles of estrogen exposure.
• Never Having Been Pregnant (Nulliparity): Pregnancy involves hormonal changes, including progesterone production, which can have a protective effect.
• Polycystic Ovary Syndrome (PCOS): This condition often leads to irregular ovulation and higher estrogen levels.
• Estrogen Replacement Therapy (ERT) without Progesterone: Hormone therapy used to manage menopausal symptoms, if it only includes estrogen, can increase risk. However, combination therapy with progesterone significantly reduces this risk.

Obesity

Being overweight or obese is a significant risk factor for endometrial cancer. Adipose (fat) tissue contains an enzyme called aromatase, which converts androgens into estrogen. In overweight individuals, this process leads to higher levels of circulating estrogen, increasing the risk of endometrial cancer, particularly after menopause.

Age

The risk of endometrial cancer increases significantly with age. Most cases are diagnosed in women over the age of 50, with the majority occurring after menopause.

Genetic Predisposition

A small percentage of endometrial cancers are linked to inherited genetic mutations. The most common inherited syndrome associated with endometrial cancer is Lynch syndrome (also known as hereditary non-polyposis colorectal cancer or HNPCC). Individuals with Lynch syndrome have a significantly increased lifetime risk of developing several cancers, including endometrial, ovarian, colorectal, and stomach cancers. Genetic counseling and testing may be recommended for individuals with a strong family history of these cancers.

Other Medical Conditions and Treatments

• Diabetes Mellitus: Type 2 diabetes is associated with an increased risk of endometrial cancer, possibly due to shared risk factors like obesity and hormonal influences.
• Tamoxifen Use: Tamoxifen is a drug used to prevent or treat breast cancer. It has anti-estrogen effects in the breast but can act as an estrogen in the endometrium, increasing the risk of endometrial polyps, hyperplasia, and cancer.
• Hypertension (High Blood Pressure): While the exact mechanism is not fully understood, hypertension is often found in women with endometrial cancer.

How Does Cancer Develop?

The progression from normal endometrial cells to cancer typically involves several stages. Initially, hormonal influences or other factors can cause the endometrium to thicken abnormally (endometrial hyperplasia). Hyperplasia can be simple (few cell changes) or complex (many cell changes), and it may or may not involve abnormal cell growth (atypia). Endometrial hyperplasia with atypia is considered a precancerous condition, meaning it has a high likelihood of developing into cancer if left untreated.

Once cancer develops, it can invade the deeper layers of the uterine wall. From the uterus, cancer cells can spread to nearby lymph nodes, the ovaries, fallopian tubes, or the lining of the abdominal cavity (peritoneum). In advanced stages, it can metastasize to distant organs like the lungs or liver.

Conclusion

In summary, endometrial cancer is primarily caused by accumulating genetic mutations in endometrial cells, often driven by prolonged exposure to estrogen without adequate progesterone. Risk factors such as obesity, age, certain medical conditions, genetic syndromes, and specific medications can significantly increase the likelihood of these mutations occurring and leading to cancer.